Tolero is a clinical-stage biopharmaceutical company with a purpose to develop effective medicines based on robust scientific research to treat cancer and other serious human diseases. Tolero has a pathway-centric pipeline of new agents aimed at targeting abnormalities in cell function in the context of pathway inhibition.

Tolero is a leader in developing novel therapeutics to inhibit biologic drivers of hematologic and oncologic diseases.

The company was founded in 2011 and was acquired in 2017 by Sumitomo Dainippon Pharma Co., Ltd. In 2012, Sumitomo Dainippon Pharma had previously acquired Boston Biomedical, Inc., a U.S.-based, fully integrated oncology and drug research company. These acquisitions expanded Sumitomo Dainippon Pharma’s oncology and hematology portfolios.

Targeted therapy is at the heart of
our pipeline.

Pipeline >

See why we’re investigating MCL-1
as a potential apoptosis inhibitor.

MCL-1 >

Learn about our clinical trials
currently underway.